PYPD

PolyPid

NASDAQ: PYPD · HEALTHCARE · BIOTECHNOLOGY

$4.08

+8.80% today

Updated 2026-07-29

Market cap

$99.51M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.74

Dividend yield

—

52W range

$3 – $6

Volume

0.2M

Market cap

$99.51M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.74

Dividend yield

—

52W range

$3 – $6

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-22.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$12.25

+200.25%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.27x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -22.89 — distress zone

- Thin margins at 0.00%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-39.52M	$-23.86M	$-29.02M	$-34.17M	$-7.73M
EPS	—	—	—	—	$-1.74
Free cash flow	$-36.08M	$-17.43M	$-22.04M	$-28.09M	—
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PYPD	$99.51M	19	4.3	3.0	5.0	5.5	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

PolyPid trades at $4.08. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -22.89, it sits in the distress.

Frequently asked questions

What is PolyPid's stock price?

PolyPid (PYPD) trades at $4.08.

Is PolyPid overvalued?

PolyPid carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of PolyPid (PYPD)?

The 12-month analyst consensus target is $12.25, about 200.2% above the current $4.08. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

PolyPid's Altman Z-Score is -22.89, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-383.02%

Beta1.40

50D MA$4.81

200D MA$4.29

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PYPD vs LLY →PYPD vs JNJ →PYPD vs ABBV →Stock screener →